| Name | Sacituzumab govitecan |
|---|---|
| Synonyms |
hRS7-SN38
IMMU-132 IMMU 132 N-[4-(-Carboxycyclohexylmethyl)]maleimide |
| Description | Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) results in significant anti-tumor effects in mice bearing human gastric cancer xenografts[1]. |
| References |
| Molecular Formula | C76H104N12O24S |
|---|---|
| Molecular Weight | 1601.77000 |
| Exact Mass | 1600.70000 |
| PSA | 499.15000 |
| LogP | 5.09770 |
| Storage condition | 2-8°C |